Zhejiang Yatai Pharmaceutical Co., Ltd. (SHE:002370)
4.500
-0.130 (-2.81%)
Nov 13, 2026, 3:04 PM CST
SHE:002370 Revenue
Zhejiang Yatai Pharmaceutical had revenue of 60.86M CNY in the quarter ending September 30, 2026, a decrease of -20.17%. This brings the company's total for the last twelve months to 313.21M, down -4.11% year-over-year. In the year 2025, Zhejiang Yatai Pharmaceutical had annual revenue of 323.14M, down -20.25%. That makes Zhejiang Yatai Pharmaceutical the 28,422nd largest company in the world by revenue and 4,856th in China.
Revenue (ttm)
313.21M
Revenue Growth
-4.11%
P/S Ratio
10.67
Revenue / Employee
612.94K
Employees
511
Market Cap
3.34B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:002370 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 323.14M | -82.04M | -20.25% |
| Dec 31, 2024 | 405.17M | -15.47M | -3.68% |
| Dec 31, 2023 | 420.64M | 47.20M | 12.64% |
| Jan 1, 2023 | 373.44M | 58.31M | 18.50% |
| Jan 1, 2022 | 315.13M | -199.75M | -38.80% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 21.33B |
| Jinhe Biotechnology CO., LTD. | 2.94B |
| Zhejiang Starry Pharmaceutical | 2.61B |
| Henan Taloph Pharmaceutical Stock Co.,Ltd | 1.70B |
| Qianjiang Yongan Pharmaceutical | 1.15B |
| Tibet Weixinkang Medicine | 1.09B |
| Shandong Wohua Pharmaceutical | 781.18M |
| Newland Pharmaceutical | 733.72M |